Asthma & COPD

This conference has already taken place.  For information on the 2010 event, please click on the link below:

COPD: Novel Therapeutics and Management Strategies 2010

For information about the 2007 Asthma & COPD conference, please see below...

OUR EXPERT PANEL OF SPEAKERS INCLUDES:

• Dr Chris Compton, Executive Director Clinical R&D, Pfizer
• Dr Craig S. Conoscenti, Senior Associate Director, Medical Affairs, Boehringer-Inglehiem
• Dr Malcolm Johnson, Global Director, Respiratory Science, GlaxoSmithKline
• Dr Sandy Goldman, Director, Respiratory Disease, Inflammation, Wyeth
• Stephen Stenglein, Clinical & Regulatory Affairs, Novartis
• Theodore Reiss, Executive Director, Respiratory & Allergy, Merck
• Thomas Eichholtz, Director of Discovery Medicine, Respiratory & Inflammation Research Area, AstraZeneca
• Dr Fred Bode, Associate Clinical Director, F. Hoffmann-La Roche
• Dr Kevin Bacon, Founder, CSO and Head of Research & Development, Actimis Pharmaceuticals
• Dr Christopher Molloy, Senior Research Fellow & Team Leader, Inflammation & Pulmonary Disease, Johnson & Johnson
• Dr Mick Hunter, Director of Drug Discovery, Oxagen
• Dr Shahin Sanjar, Senior Director Respiratory Sciences, Altana
• Dr Woodruff Emlen, CEO, Taligen Therapeutics
• Dr Göran Tornling, Vice President & Chief Medical Officer, Biolipox
• Dr Paolo Renzi, Chief Scientific Officer, Topigen Pharmaceuticals
• Peter Kiener D.Phil, Senior Vice President, Research, MedImmune
• Dr Charles R Penn, Chief Operating Officer, Syntaxin

The conference will be chaired by;
• Dr Michael Rudolf, Consultant Respiratory Physician, Ealing Hospital and Past Chairman, British Thoracic Society COPD Consortium
• Neil Barnes, Consultant Respiratory Physician, Barts & The London NHS Trust

If you attend one respiratory conference this year this should be the one! Nowhere else will you find such a diverse speaker line- up, mix of topics and in-depth coverage of the industry!

BENEFITS OF ATTENDING ASTHMA & COPD

GAIN a valuable insight into the current pipeline developments in the respiratory arena
IDENTIFY new drug developments and concepts
REVIEW the clinical endpoints that are currently being accepted
EXAMINE the development and use of biomarkers in Asthma & COPD
HEAR case studies from the world leaders in respiratory drug discovery

WHO SHOULD ATTEND ASTHMA AND COPD

You should attend this conference if you are an Executive, Director or scientist working in the pharmaceutical or biotech industries within:

Respiratory Science	Research & Development
Inflammation	Clinical & Regulatory Affairs
Drug Discovery	Respiratory Illness
Inhalation Drug Delivery	Project Management
Preclinical Development	Portfolio Management
Marketing

WHO WILL YOU MEET AT ASTHMA & COPD?

A sample of the companies already in attendance includes:

“Great speaker diversity – topics & research” Kim Kuebler, Medical Scientist, Boehringer-Ingelheim It is estimated that the global annual sales in the asthma and COPD market are due to increase by over $10 billion US dollars within the next 5 years and then remain flat thereafter. Will you make use of this transforming market & increasing potential before it’s too late? Through a series of case studies from the leading pharmaceutical companies SMi’s 3rd annual conference on Asthma & COPD will explore the new drugs in the R&D pipeline. The conference will examine the mortality levels in asthma and COPD, inspect the emerging novel treatments and drug therapies and highlight the development and use of biomarkers through to the use of clinical endpoint in Asthma & COPD.

This is your exclusive opportunity to benchmark your company by hearing from the industry leaders already at the forefront of this dynamic market.